Company is investing $2.8bn in two Irish plants to produce its in-demand weight loss drugs and a new Alzheimer’s therapy ...

Headlines,Novo Nordisk experienced a decline in stock value after recent news from its lab.,Eli Lilly, (NYSE:LLY),and Viking ...

How Eli Lilly’s Next 5 Years Could Play Out We expect Eli Lilly’s P/E ratio in 2025 to be 60 with an EPS of $19.11, resulting in a price target of $1140.00 This prediction is based on strong ...

Eli Lilly's valuation is a critical concern, but its robust execution has improved its ability to actualize its high-growth ...

Feel free to distribute or cite this material, but please credit OpenSecrets. For permission to reprint for commercial uses, such as textbooks, contact OpenSecrets: [email protected] ...

With a market capitalization of over $800 billion, Eli Lilly (NYSE: LLY) is the largest pharmaceutical company in the world.

Lilly clearly has an abundance of growth drivers -- and the list includes more than Mounjaro, Zepbound, and the six drugs ...

Eli Lilly will invest $1.8 billion to boost manufacturing for its newly approved Alzheimer's drug and highly popular weight ...

Eli Lilly's long-term growth prospects are strong with improved supply, new growth opportunities, and competitive positioning ...

Full-service independent pharmaceutical marketing and communications agency RevHealth, a 2024 MM+M Agency 100 honoree, named former 21Grams and Wunderman Thompson Health exec William Martino as chief ...

Eli Lilly (NYSE: LLY) stands atop the biopharmaceutical ... Lilly's pipeline features several late-stage candidates that should have major commercial potential. The company is evaluating ...